Biologics for asthma are targeted medicines made using living cells that block specific parts of the immune system involved in airway inflammation. They are usually added to treatment when asthma remains difficult to control with standard medicines, such as inhalers. Each biologic targets a different immune signal, helping reduce inflammation and asthma flare-ups in people with certain types of asthma.
What Does Biologics Mean in Asthma Treatment?
Biologics are medicines designed to act on specific proteins, antibodies, or cells involved in a disease. Many asthma biologics are called monoclonal antibodies. These are specially designed proteins that recognize and attach to a particular target in the immune system.
In asthma, the immune system can produce inflammatory signals that cause the airways to swell, become sensitive, and produce extra mucus. These changes can contribute to coughing, wheezing, chest tightness, and difficulty breathing.
Different people may have different immune pathways driving their asthma. Some have inflammation linked to allergic reactions, while others have inflammation involving a type of white blood cell called an eosinophil.
According to the American Academy of Allergy, Asthma & Immunology (AAAAI), asthma biologics target particular antibodies, inflammatory molecules, or cell receptors involved in these processes. This makes them a form of targeted or precision treatment.
How Do Biologics Work for Asthma?
Biologics work by interrupting specific immune signals that contribute to inflammation in the airways. Rather than treating every part of the immune system, each medicine focuses on a particular target involved in an asthma-related inflammatory pathway.
For example, one biologic may block an antibody involved in allergic reactions, while another may interfere with the signals that activate eosinophils. By interrupting these processes, the medicines can reduce inflammation and lower the likelihood of asthma flare-ups.
The treatment does not work by immediately relaxing the muscles around the airways. Instead, it helps control the underlying inflammatory processes over time.
What Are the Different Types of Asthma Biologics?
Asthma biologics are grouped according to the immune target they block. The main groups include treatments targeting IgE, interleukin-5, the interleukin-4 receptor, and thymic stromal lymphopoietin.
1. Anti-IgE biologics for allergic asthma
IgE, or immunoglobulin E, is an antibody involved in allergic reactions. In some people with asthma, exposure to allergens can activate immune pathways involving IgE and contribute to airway inflammation.
Omalizumab is an example of an anti-IgE biologic. It attaches to free IgE in the blood, preventing it from interacting with certain immune cell receptors. This reduces the allergic signaling process involved in asthma inflammation.
Anti-IgE treatment may be considered for people with severe allergic asthma who meet the relevant clinical and testing criteria.
2. Anti-IL-5 and anti-IL-5 receptor biologics for eosinophilic asthma
Interleukin-5 (IL-5) is an immune signaling protein that helps regulate the production, growth, and survival of eosinophils. Eosinophils are white blood cells that can contribute to airway inflammation in certain types of asthma.
Some biologics block IL-5 itself, while others target its receptor on eosinophils. These treatments help reduce the activity or number of eosinophils involved in inflammation.
Examples include:
- Mepolizumab: Blocks IL-5, reducing signals that support eosinophils.
- Reslizumab: Also blocks IL-5 and helps reduce eosinophilic inflammation.
- Depemokimab: A longer-acting treatment that targets IL-5.
- Benralizumab: Attaches to the IL-5 receptor on eosinophils and promotes their removal.
These medicines are mainly considered for people with severe eosinophilic asthma who meet the relevant treatment criteria.
3. Anti-IL-4 receptor biologics
Interleukin-4 (IL-4) and interleukin-13 (IL-13) are signaling proteins involved in Type 2 inflammation. This inflammatory pathway contributes to allergic responses and airway changes in some people with asthma.
Dupilumab is an example of an anti-IL-4 receptor biologic. It blocks the IL-4 receptor alpha, which interferes with the signaling effects of both IL-4 and IL-13.
Doctors may consider this treatment for selected people with severe asthma associated with Type 2 inflammation or eosinophilic asthma. It may also be an option for certain people who need ongoing oral corticosteroids to control their asthma.
4. Anti-TSLP biologics
Thymic stromal lymphopoietin (TSLP) is a signaling protein released by cells lining the airways. It acts as an early warning signal that can activate several inflammatory pathways involved in asthma.
Tezepelumab is an example of an anti-TSLP biologic. It attaches to TSLP and prevents this signal from activating downstream inflammatory processes.
Because TSLP is involved in several inflammatory pathways, this treatment may be considered for selected people with severe asthma even when typical allergic or eosinophilic markers are not elevated.
The Global Initiative for Asthma (GINA) 2026 Severe Asthma Guide describes these four major treatment targets and explains how clinicians select biologics according to asthma characteristics and the likelihood of treatment response.
Who May Need Biologic Treatment for Asthma?
Biologics are generally considered when asthma remains poorly controlled despite appropriate use of standard controller medicines and other recommended management measures. They are not usually the first treatment prescribed after an asthma diagnosis.
They may be considered for people who experience:
- Repeated asthma flare-ups despite regular controller treatment.
- Persistent breathing symptoms despite appropriate inhaled medicines.
- Repeated need for oral corticosteroids to manage asthma exacerbations.
- Hospital admissions or emergency visits related to uncontrolled asthma.
- Evidence of allergic or eosinophilic inflammation that matches a particular biologic treatment.
Before considering a biologic, healthcare professionals review whether the asthma diagnosis is correct and whether other factors are contributing to poor control. These may include incorrect inhaler technique, missed doses, ongoing exposure to triggers, or other medical conditions.
The 2026 GINA guidance recommends considering targeted biologics for appropriately selected people with severe asthma after treatment has been optimized. Persistent symptoms alone do not automatically mean that someone needs a biologic.
What Tests Help Doctors Choose an Asthma Biologic?
There is no single test that determines which biologic is suitable for everyone. Doctors combine laboratory results with symptoms, medical history, previous asthma flare-ups, current medicines, and lung function findings.
Some of the tests and assessments may include:
Blood eosinophil count
This blood test measures the number of eosinophils, a type of white blood cell involved in certain forms of airway inflammation. Higher levels may support the possibility of eosinophilic asthma and help assess eligibility for some anti-IL-5 or anti-IL-5 receptor treatments.
IgE blood testing and allergy testing
Doctors may measure total IgE levels and look for sensitivity to particular allergens using specific IgE blood tests or skin prick testing. These findings can help determine whether an anti-IgE treatment may be appropriate.
Fractional exhaled nitric oxide (FeNO) test
FeNO is a breathing test that measures the amount of nitric oxide in exhaled air. Higher levels can suggest Type 2 airway inflammation and may help guide decisions about certain biologics.
Lung function testing
Spirometry measures how much air a person can breathe out and how quickly they can do so. It helps doctors assess airflow limitation and monitor asthma control over time.
The Asthma and Allergy Foundation of America (AAFA) explains that biomarkers such as IgE, eosinophils, and FeNO can help identify inflammatory patterns and guide the selection of asthma biologics.
Test results are interpreted together with clinical findings. The eligibility thresholds for individual medicines can differ according to the drug, age group, country, and local treatment requirements.
How Are Asthma Biologics Given?
Most asthma biologics are given as injections under the skin, also called subcutaneous injections. Some are given through an intravenous infusion, which delivers the medicine directly into a vein.
The method and frequency depend on the specific biologic. Treatment schedules can range from injections every few weeks to longer intervals of several months.
Depending on the medicine and individual circumstances:
- Some injections are given by a healthcare professional in a clinic or hospital.
- Some treatments can be administered at home after appropriate training.
- Certain medicines require observation after administration because of the possibility of allergic reactions.
- Regular appointments may be needed to assess treatment response and monitor safety.
For example, the National Library of Medicine's MedlinePlus information on tezepelumab explains that this medicine is given as an injection under the skin, usually once every four weeks. It can be administered by a healthcare professional or by a trained patient using an appropriate prefilled pen.
What Benefits Can Asthma Biologics Provide?
For people who are suitable candidates, biologics can improve asthma control by reducing inflammation through targeted immune pathways.
Potential benefits include:
- Fewer severe asthma flare-ups.
- Reduced need for emergency visits and hospital admissions.
- Fewer symptoms, such as wheezing, coughing, and breathlessness.
- Improved lung function in some people.
- Reduced need for oral corticosteroids in certain treatment groups.
- Improved ability to manage daily activities and overall quality of life.
The extent of improvement depends on the type of asthma, the biologic selected, and the person's response. Some people experience substantial benefits, while others may have a limited response.
Biologics are not immediate-relief medicines. Improvements may take several weeks to become noticeable, and doctors usually evaluate the response over a period of months.
Can Asthma Biologics Replace Inhalers?
No. Asthma biologics are generally used as additional controller treatments rather than replacements for standard asthma medicines.
Inhaled corticosteroids remain an important part of asthma management because they reduce airway inflammation through a different mechanism. Other inhalers may also be needed to help prevent symptoms or keep the airways open.
Biologic treatment may allow a healthcare professional to reduce some existing medicines when asthma control improves. However, maintenance inhalers should not be stopped or reduced without medical guidance.
Biologics also do not replace quick-relief medicines used according to an asthma action plan during sudden breathing symptoms. They are designed for ongoing disease control, not immediate relief during an asthma attack.
What Are the Possible Side Effects of Asthma Biologics?
Asthma biologics are generally well tolerated, but side effects can occur. The possible reactions vary according to the medicine and the individual receiving it.
Some reported side effects include:
- Redness, swelling, or discomfort at the injection site.
- Headaches.
- Sore throat.
- Joint pain.
- Fatigue.
- Skin reactions or rashes.
Rarely, a biologic may cause a serious allergic reaction called anaphylaxis. Symptoms can include difficulty breathing, swelling of the face or throat, widespread itching, dizziness, or fainting. These symptoms require immediate emergency medical attention.
Omalizumab has a specific warning about serious allergic reactions, which may occur after an injection or during treatment. The MedlinePlus information on omalizumab explains why initial treatment may be given in a healthcare setting with observation for allergic reactions.
Before starting treatment, patients should discuss their medication history, previous allergic reactions, existing health conditions, and possible treatment risks with their healthcare professional.
Are Biologics Used for Asthma in Children?
Yes. Some biologics are approved for children with particular types of asthma, but eligibility depends on the medicine, the child's age, and the nature of the inflammation.
For example, certain biologics may be used from six years of age, while others have approval for adolescents or adults only. Treatment requirements and approved age groups can also differ between countries.
For children, specialists consider factors such as body weight, blood test results, asthma flare-up history, previous treatment response, and the specific medicine's approved age range.
A pediatric respiratory specialist or allergy specialist can help determine whether a biologic is an appropriate additional treatment for a child whose asthma remains difficult to control.
How Long Do People Need to Take Asthma Biologics?
The length of treatment depends on how well the biologic controls asthma and whether its benefits continue over time.
Doctors generally monitor several factors when reviewing treatment response, including:
- How often asthma flare-ups occur.
- Whether symptoms and nighttime breathing problems have improved.
- Changes in lung function.
- Whether the need for oral corticosteroids has decreased.
- Any side effects or difficulties with treatment.
The 2026 GINA severe asthma guidance recommends an initial treatment trial of at least four months for many targeted biologics, with longer assessment periods for certain medicines. If the response is not satisfactory, the specialist may reconsider the treatment choice or assess whether another factor is contributing to poor asthma control.
People who respond well may need to continue their biologic for an extended period. Decisions about continuing, changing, or stopping treatment should be made with the treating specialist.
Are Asthma Biologics a Cure?
No. Biologics do not permanently cure asthma. They help control specific inflammatory pathways that contribute to the condition.
For suitable patients, these treatments can reduce flare-ups, improve symptoms, and decrease the need for some other medicines. However, asthma may remain an ongoing condition requiring regular monitoring and maintenance treatment.
The main purpose of biologic therapy is to achieve better long-term asthma control and reduce the impact of the disease on everyday life.